4,5 It was a relatively small trial as the primary objective of the trial was to confirm that treatment with oral semaglutide does not result in an unacceptable increase in cardiovascular risk compared with placebo in patients with a high risk of cardiovascular events
10.1056/NEJMoa2032183 [DOI] [PubMed] [Google Scholar] Willard F
The study population included 85,223 patients with obesity who were prescribed semaglutide or non-GLP-1RA anti-obesity medications, with the findings replicated in 596,045 patients with T2D
The muscle mass preserved through resistance training supports a higher metabolic rate, making maintenance easier
The most commonly reported adverse effects of Wegovy include: Gastrointestinal symptoms : nausea, vomiting, diarrhoea, constipation, and abdominal discomfort Injection site reactions : redness, itching, or mild swelling at the injection site Fatigue or headache in some individuals These side effects are generally mild to moderate and tend to diminish as the body adjusts to the medication, particularly during the gradual dose-escalation schedule designed to improve tolerability